Harry Potter: Puzzles & Spells Welcomes Winter Holidays with Christmas-themed Collection Event, New Magical Creature and Social Surprises Throughout December
Zynga Inc. (Nasdaq: ZNGA):
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201222005003/en/
Harry Potter: Puzzles & Spells Welcomes Winter Holidays with Christmas-themed Collection Event, New Magical Creature and Social Surprises Throughout December (Graphic: Business Wire)
WHO:
Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced that winter holiday celebrations are rolling out in its recently released mobile game Harry Potter: Puzzles & Spells. Officially licensed from Warner Bros. Games and published under the Portkey Games label, players of the game will be treated to a series of seasonal festivities throughout December, ranging from special limited-time collection events to a host of holiday decor and surprises.
WHAT:
In the game, players can collect cards to complete the new, limited-time ‘Christmas in the Wizarding World’ album to earn a mythical Unicorn as their companion magical creature. Later in the month, holiday decor and weather will turn Hogwarts into a wintry, wizarding wonderland as players encounter falling snowflakes on their gameboard that can be collected to earn rewards. Bringing a bang to the festivities, brightly colored ‘Wizard Cracker’ boosts will drop into the puzzles unexpectedly, giving players the gift of an extra gem-clearing blast as they complete puzzles in this magical Match-3 game.
Bringing style to the season, international artist and known Harry Potter fan Zayn Malik has worked closely with the Zynga team to create new customization elements for the magical Match-3 title. To replicate more life-like features for his avatar in Harry Potter: Puzzles & Spells, Zayn worked to create new eyebrow, earring, beard and eye customizations that will be available in-game to all players in the new year. Malik has shared artwork of his in-game avatar on his own social channels in December, with an invitation for his fans and fellow gamers to share images of their own.
Additionally, as the calendar arrives at Christmas Eve, players can also visit the Harry Potter: Puzzles & Spells social channels for more surprises and holiday cheer during the last week of the year.
QUOTES:
“I really enjoyed working with the Zynga team coming up with new elements to the avatar creator,” said Zayn Malik. “I feel like seeing the animated version of myself in the game made it way more fun and with these new customizations that are coming soon, all players will have the opportunity to feel more connected to the game and make their character look more like themselves!”
“As any fan of the Harry Potter books and films knows, Christmas at Hogwarts is a very special time,” said Yaron Leyvand, Senior Vice President of Games at Zynga. “For the first winter holiday for Harry Potter: Puzzles & Spells, we wanted to treat players to a range of new content and seasonal rewards, released throughout December. We’re excited to celebrate the season with players and also have many more magical Match-3 events and activities in store for next year.”
BACKGROUND:
In Harry Potter: Puzzles & Spells, players enter a Match-3 adventure brimming with the spells, humour, colour and characters of the Harry Potter series. Featuring the soundtrack and voiceover recordings from the original Harry Potter films, fans follow an authentic, mobile retelling of Harry’s journey through the wizarding world. Earning spells and special boosts as they advance, players solve Match-3 puzzles populated with hopping Chocolate Frogs, fluttering Winged Keys, battling wizard chess pieces and other unexpected obstacles and objects. In the spirit of camaraderie and friendly competition at Hogwarts, players can join or form clubs with other fans to socialise, collaborate on puzzle strategies, share lives and vie for prizes in exclusive Club Events.
Harry Potter: Puzzles & Spells is playable on iOS and Android devices worldwide, as well as on Amazon Kindle and Facebook. For more information and to connect with other fans, follow us on Facebook, Instagram and Twitter, and visit the game’s website at www.harrypotterpuzzlesandspells.com.
SUPPORTING ASSETS:
Supporting visual assets available at: https://bit.ly/HPPSHoliday
About Zynga
Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR Racing
TM, Empires & Puzzles
TM, Merge Dragons!
TM, Merge Magic!
TM, Toon Blast
TM, Toy Blast
TM, Words With Friends
TM and Zynga Poker
TM. Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter, Instagram, Facebook or the Zynga blog.
About Warner Bros. Games
Warner Bros. Games, a division of Warner Bros. Home Entertainment, Inc., is a premier worldwide publisher, developer, licensor and distributor of entertainment content for the interactive space across all platforms, including console, handheld, mobile and PC-based gaming for both internal and third-party game titles. Additional information about Warner Bros. Games can be found at https://www.wbgames.com/.
About Portkey Games
Portkey Games, from Warner Bros. Interactive Entertainment, is the games label dedicated to creating new Wizarding World mobile and videogame experiences that place the player at the center of their own adventure, inspired by J.K. Rowling’s original stories. Portkey Games offers players the opportunity to make their own narrative choices and engage with the Wizarding World setting to create new and unique experiences. The label was created to bring gamers and fans new gaming experiences that allow them to delve into the magic of the Wizarding World in immersive ways where they can define their own Wizarding World story.
Forward Looking Statements
This press release contains forward-looking statements relating to, among other things, gameplay details, game features, and a limited-time holiday event and the expectation of additional events and features in 2021 in Harry Potter: Puzzles & Spells. Forward-looking statements often include words such as “outlook,” “projected,” “planned,” “intends,” “will,” “anticipate,” “believe,” “target,” “expect,” and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties, and assumptions is or will be described in greater detail in our public filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained by visiting our Investor Relations website at http://investor.zynga.com or the SEC’s website at www.sec.gov.
WIZARDING WORLD, HARRY POTTER Publishing Rights © J.K. Rowling. HARRY POTTER: PUZZLES & SPELLS, PORTKEY GAMES, WIZARDING WORLD and HARRY POTTER characters, names and related indicia © and ™ Warner Bros. Entertainment Inc. ™ Zynga Inc. All Rights Reserved.
WB SHIELD: ™ & © Warner Bros. Entertainment Inc. (s20)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201222005003/en/
Contact information
ZYNGA MEDIA CONTACT:
Dana Whitney | dwhitney@zynga.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 15:00:00 EET | Press release
Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evaluated as presenting the true 'Gold Standard' in regenerative medicine by perfectly resolving the inherent challenges—such as immune rejection, incomplete reprogramming, and the inheritance of aging—that have been cited as limitations of existing stem cell therapies. Clonell's SCNT technology establishes a patient-specific embryonic stem cell line by transferring the nucleus of a patient's somatic cell into a healthy enucleated oocyte. This process
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi ® /Minjuvi ® ) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 14:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years of age, or age-adjusted IPI (aaIPI) of two to three (2-3) for patients ≤60 years of age. The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment (Hazard Ratio 0.75 [0.59,0.96]; p-value 0.019), according to Lugano 2014 criteria. The trial also met its key secondary endpoint of event-free survival (EFS) by investigator assessment. No new safety signals were observed. “The frontMIND stud
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 14:30:00 EET | Press release
Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, today announced that the Company will operate under the business name Helus Pharma (pronounced “Heal-Us”) and trade on Nasdaq with ticker symbol HELP. “Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004,” said Eric So, interim chief executive officer of the Company. “Over the past several years, we have advanced our pipeline portfolio of differentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted. We are approaching the commercialization of HLP003 with strong clinical data and significant market potential, subject to the
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 14:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV. “This is an important milestone toward our goal of addressing critical gaps that patients living with polycythemia vera face today,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “The comprehensive VERIFY study data underscore rusfertide’s strong clinical profile and potential to provide sustained hematocrit control while reducing phlebotomy and symptom burden. Our collaboration with Protagonist exemplifies how partnerships can advance innovative science, with a focus on m
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance with a Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom